SCHEMBL4258804

SCHEMBL4258804

SCCCn1cnc2cccnc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
PABPC1 P11940 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.38
LMNA P02545 3/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CSF1R P07333 1/20 0.36
MAPT P10636 3/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
HTT P42858 2/20 0.35
HSD17B10 Q99714 1/20 0.35
STAT3 P40763 1/20 0.35
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019976 0.90 MEN1 (0.49) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL5015508 0.85 MEN1 (0.51) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL454840 0.83 MEN1 (0.47) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4258800 0.83 MEN1 (0.47) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL13749571 0.82 MEN1 (0.46) MEN1TP53PABPC1KMT2ASMN1; SMN2
SCHEMBL4232433 0.82 MEN1 (0.46) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL8656006 0.82 MEN1 (0.46) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL13527216 0.81 MEN1 (0.45) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL13870062 0.80 MAPK13 (0.45) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4019974 0.79 MEN1 (0.49) MEN1TP53PABPC1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846430-B1 NEW MACROLIDES BASILEA PHARMACEUTICA AG (CH) 2009-04-01 EP disclosed
EP-1313751-B1 NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2008-09-17 EP disclosed
US-6740642-B2 ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY BASILEA PARMACEUTICA AG (CH) 2004-05-25 US disclosed
US-20030199459-A1 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199459-A1 Macrolides with antibacterial activity MRPL21, MRPS22, MRPL12 MEN1 1230/4885TP53 4864/4885PABPC1 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.